LinkedIn (Matthew Hardy) | LinkedIn Company | X/Twitter (Matthew Hardy) | X/Twitter Company | Instagram | Facebook | Print -
NomosLogic: Defining a Category in Molecular Medicine Infrastructure
Matthew Hardy
Founder and CEO
NomosLogic Inc.
Contact
Matthew Hardy
801.810.7009
Follow NomosLogic
LinkedIn: https://www.linkedin.com/in/matt-
LinkedIn Company: https://www.linkedin.com/company/nomoslogic-
X/Twitter: https://x.com/MatthardyNomos
X/Twitter Company: https://x.com/NomosLogic
Instagram: https://www.instagram.com/nomoslogicinc/
Facebook: https://www.facebook.com/nomoslogic
Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFO Magazine
Published – June 22, 2026
CEOCFO: Mr. Hardy, what is the idea behind NomosLogic?
Mr. Hardy: NomosLogic exists because I was the first patient. I spent years in the healthcare system; I had access to my data, but no architecture to read it correctly. I had symptoms, prescriptions, and specialists, but I wasn’t getting any coherent answers. I had a DNA file that had been sitting around since 2016, and access to that data that was available. What I did was I built a system to get the answers that doctors weren’t providing. What I found was clinically meaningful, adverse medication risks and drug interactions that should have surfaced years earlier.
There were safety signals that standard care didn’t have a framework to read, and genetic factors that my doctors couldn’t connect. That told me something specific, there was a problem, and the problem wasn’t missing data. The data existed; the problem was architecture in healthcare. They had no way to read the information that they already had. That is why NomosLogic exists today.
CEOFO: What were the challenges in creating that system?
Mr. Hardy: Nomenclature translation is the big problem. Something that we have patented is our Hardy Bridge, which is that nomenclature translation. There are over 40 different nomenclatures out there that all call the same thing something different in translation. Part of the problem with modern medicine is there is no way to translate that nomenclature. We normalize them, so all of the meanings from those nomenclatures are transcribed the same.
CEOCFO: Once you recognized that problem, were the steps there technologically, had it not been done before, or did you have to invent new ways?
Mr. Hardy: The steps were there. I approached it a little differently, because my history is different than most. I have a background in biology. I was a premed student going into diagnostic medicine. Then I spent the last 30 years in systems architecture. Therefore, I approached this problem as a systems architect and not as a biologist. I think that is one of the things that medicine is not seeing is that the architecture is actually there.
CEOCFO: Does the medical community recognize there is a problem?
Mr. Hardy: I think they do, I just don’t think that they have figured out how to solve it, and that is where we come in.
CEOCFO: How do you get from having a solution to the people needing to know about it, understanding and using it?
Mr. Hardy: Contacts, partnerships, conferences, getting it out there, and literature. I have written a couple of books on the subject. It is creating those contacts and getting in touch with the right people, the right doctors, the right payers, the right people at pharma companies, and bringing everyone together and unifying everyone for meaningful partnerships.
CEOCFO: Was there a lightbulb moment when you are presenting or talking to someone that knows the topic, when they say “oh yeah, that’s it.” How do you get it across?
Mr. Hardy: I see that often and usually it takes some conversation because genomics has been studied the same way for the last 30 years. People are focused on single dominant variants and assume they are the pathogenic variants, then think those are the things we need to focus on.
What they haven‘t seen is how biological structures re-
CEOCFO: Could you walk us through a scenario of a medical condition and how your system might be used?
Mr. Hardy: Let’s take for instance something that I have personally faced. I have gastrointestinal problems, and I have for years. I suffer anemia yet I don’t have any bleeding internally. Doctors have struggled to figure out why. Through my system I identified that I have a CFTR variant, generally found in cystic fibrosis. If you are homozygous and have the CFTR variant, then you are at risk of having cystic fibrosis and generally you have a very short life. I am heterozygous, so I only carry one side.
What it is, is a tumor suppressor for gastrointestinal cancer. It also affects how you absorb iron. My system identified that in a matter of minutes. I took the reports to the doctors and they did scopes and found polyps that they wouldn’t have found otherwise, and probably prevented me from getting gastrointestinal cancer, and saved my life. Now I am being treated properly because the doctors know what is really going on with my body.
CEOCFO: How does this relate to genetic testing, and is genetic testing a place to start?
Mr. Hardy: Absolutely! And something that is unique to NomosLogic, is we can resolve consumer DNA. There are already 70 million people out there that have their genetic tests done for ancestral purposes, whether it be Ancestry.com, 23&Me, or My Heritage. You can use the DNA files and run them through our system and get these answers that matter.
CEOCFO: I understand you are going to be at Bio International; how do you stand out at a conference when there are so many new ideas?
Mr. Hardy: I don’t know that I have the direct answer to that. What we are doing, is trying to have those right conversations up front, and set up partnership meetings. We aren’t anyone’s competition. We are the infrastructure layer for the world of molecular medicine. We are the roads that connect the cities. We provide a benefit to almost everyone out there whether it be a sequencing company, hospital, point of care, pharma, drug research, payers and insurance companies. We can provide something for everyone because we connect it all together.
CEOCFO: Is there a product available for sale today?
Mr. Hardy: Yes, everything we have is in production. We are ready for any partner that wants to start using it, including consumers. We are Smart on FHIR ready, so we can plug right into the EHR system. We are payer ready, so payers can embed us in their benefits. We are drug discovery ready, so pharma can use us for targeting in drug discovery.
CEOCFO: Would you tell us about ease of use, and what is involved in implementation?
Mr. Hardy: If you are Smart on FHIR, it is as simple as installing the plugin and you are ready to go. Otherwise, it is just a matter of setting up a contract with us and setting up your account, and then you are good to go. If you want to use us as a standalone application, it is very easy.
We have to figure out what those contracts look like depending on what you are doing and what you are going to be using it for, because it is Logic as a Service. Whatever pieces you want to use, you can choose, or, you can do it as a package. We have a number of ways to plugin with us.
CEOCFO: What surprised you as you’ve started to develop this to where you are today?
Mr. Hardy: I didn’t develop it to be a commercial product. I developed it to find answers for myself. As I am doing this, and getting these answers to my own health questions, I realized how bad the healthcare system has failed society. We have all of this information fragmented and we are treating people like averages.
Something that I am really proud of is called ancestral adaptation. Today, genomics treats almost everyone as a population average, and that average is a European population average. So if you come from a different region of the world, then your genetic frequencies are much different. Take for example the malaria belt, and what we call pathogenic in the sickle cell variant. If you are heterozygous for a sickle cell variant, you have an 80% chance of survival from malaria and that is not by chance. That is one of the highest evolutionary pressures that humanity has ever seen. Here in the West, we call that pathogenic. If you are in the malaria belt, that is a survival mechanism.
We need to stop treating everyone like an average. That is something NomosLogic provides. It takes your evolutionary history into perspective. It takes those frequencies into account. Precision medicine is here and it is time we start using it instead of doing things the old way.
CEOCFO: Are you seeking funding or investment, and partnerships?
Mr. Hardy: We haven’t actively been looking for funding. We are certainly open to the conversations today. We may start having those conversations with the right investors who share our mission. We have been self-
CEOCFO: You have a number of different items in your integrated stack. Would you tell us about Covenant; I see it resolves human genomes in 28 seconds?
Mr. Hardy: I will tell you why it is unique. For example, let’s say a children’s research hospital, pediatric oncology, they are looking for very specific things on trying to identify variants and patterns in children’s genetically linked cancer. Today, it uses machine learning which is probabilistic.
One thing about NomosLogic is that we are deterministic, the same data in, the same data out, every single time. We don’t guess. We don’t say yes or no, we say yes, no, or unknown. That is a no-
CEOCFO: What does the next year look like for Nomos?
Mr. Hardy: Next year looks like building those partnerships and scaling.
CEOCFO: What if anything should people understand about NomosLogic that we haven’t discussed?
Mr. Hardy: They should understand they have the data, they should take advantage of that data. Let’s change the way that modern healthcare is practiced. It is time to move into the next generation of healthcare, and that is precision healthcare. Nobody should be treated like an average, everyone should get personalized healthcare regardless of who they are.
NomosLogic Inc. | Deterministic Molecular Medicine Infrastructure | Matthew Hardy | NomosLogic: Defining a Category in Molecular Medicine Infrastructure | CEO Interviews 2026 | Medical Companies | NomosLogic | Matthew Hardy NomosLogic | Matt Hardy genomics | Matthew Hardy deterministic convergence | deterministic molecular medicine | pharmacogenomics | pharmacogenomic testing | pharmacogenomic decision support | drug-